Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tendyne transcatheter mitral valve shows sustained benefits at 2 years

Key clinical point: Eighty-two percent of patients were NYHA class I or II at 2 years.

Major finding: At 2 years of follow-up, 93% of recipients of the Tendyne valve had no mitral regurgitation.

Study details: This is a prospective open-label study of long-term outcomes in the first 100 patients who underwent transcatheter mitral valve replacement with the Tendyne device.

Disclosures: The presenter reported receiving research grants from and serving as a consultant to Abbott, the study sponsor, as well as Edwards Lifesciences and Medtronic.


Muller DWM et al. EuroPCR 2020.